PedAM

Pediatric Disease Annotations & Medicines

Disease	adenocarcinoma
Phenotype	C0004763\|barrett esophagus
Sentences	6
PubMedID- 22219077	[risk of adenocarcinoma in patients with barrett esophagus is significantly less than previously assumed].
PubMedID- 21857838	barrett esophagus with progression to adenocarcinoma in multiple family members with attenuated familial polyposis.
PubMedID- 21593708	Incidence of esophageal adenocarcinoma with barrett esophagus (be) imposes a decision about therapy management.
PubMedID- 25502158	The goal of this study was to determine whether the use of metformin modifies the risk of development of esophageal adenocarcinoma in patients with barrett esophagus.
PubMedID- 24570884	In the united states, the burden of esophageal cancer in 2007 was 16,640 new cases and 14,500 deaths with a 5-year survival rate of only 15%.1 of these cases, 65% were adenocarcinoma associated with barrett esophagus (be).
PubMedID- 25621687	The incidence of esophageal adenocarcinoma arising from barrett esophagus (be) has been rapidly increasing in many western countries over the past few decades.1–3 it also leads to increasing the rate of hospitalization for esophageal adenocarcinoma and causes a serious problem.4 endoscopic surveillance of be, the currently accepted standard, aims to reduce morbidity and mortality by early detection and endoscopic therapy of dysplasia or cancer.5–8 current guidelines from gastroenterology societies recommend endoscopic surveillance of be using white light endoscopy (wle) with targeted biopsies of any endoscopically visible lesions and 4 random quadrant biopsies from every 2 cm of the be segment (seattle protocol).7,9 however, it has been pointed out that this protocol has several limitations, such as time required, low compliance, and increased risk of sampling error.10 therefore, establishment of a more effective surveillance program for detecting dysplastic lesions or those with high malignant potential in be patients is highly desirable.

Page: 1